Estimation of endoplasmic reticulum aminopeptidase 1 level of expression in lesional and nonlesional skin of psoriatic patients and healthy controls

Background Psoriasis is a chronic inflammatory autoimmune disease of the skin, in which an elevated expression of endoplasmic reticulum aminopeptidase 1 (ERAP1), an enzyme involved in the final processing of major histocompatibility complex-I ligands, was reported. No previous reports studied the le...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Dina Metwally (Autore), Laila A Rashed (Autore), Amul M Badr (Autore), Doaa M Elqadi (Autore), Rana F Hilal (Autore)
Natura: Libro
Pubblicazione: Wolters Kluwer Medknow Publications, 2021-01-01T00:00:00Z.
Soggetti:
Accesso online:Connect to this object online.
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_844e906afee74929b644d7afef3fb16c
042 |a dc 
100 1 0 |a Dina Metwally  |e author 
700 1 0 |a Laila A Rashed  |e author 
700 1 0 |a Amul M Badr  |e author 
700 1 0 |a Doaa M Elqadi  |e author 
700 1 0 |a Rana F Hilal  |e author 
245 0 0 |a Estimation of endoplasmic reticulum aminopeptidase 1 level of expression in lesional and nonlesional skin of psoriatic patients and healthy controls 
260 |b Wolters Kluwer Medknow Publications,   |c 2021-01-01T00:00:00Z. 
500 |a 2090-2565 
500 |a 10.4103/jewd.jewd_5_21 
520 |a Background Psoriasis is a chronic inflammatory autoimmune disease of the skin, in which an elevated expression of endoplasmic reticulum aminopeptidase 1 (ERAP1), an enzyme involved in the final processing of major histocompatibility complex-I ligands, was reported. No previous reports studied the level of ERAP1 in lesional and nonlesional skin of psoriatic patients. Objective To estimate the level of ERAP1 expression in lesional and nonlesional skin of psoriatic patients and the skin of healthy controls to define its role in the pathogenesis of psoriasis. Patients and methods In this case-control study, 25 psoriatic patients and 30 healthy, age-matched and sex-matched controls were enrolled. All patients were subjected to detailed history and clinical examination, including Psoriasis Area and Severity Index (PASI) score to determine severity of psoriasis. Skin biopsies were obtained from all participants: two from psoriatic patients (lesional and nonlesional) and one from healthy controls. ERAP1 level was measured using PCR technique. Results There was a highly significant level of expression of ERAP1 in psoriatic lesions when compared with control skin (P<0.001). Moreover, ERAP1 in nonlesional tissue in psoriatic patients was significantly higher than in controls (P<0.001). ERAP1 expression in lesional tissue was higher than that in nonlesional tissue, but without a significant difference. Moreover, a positive correlation was detected between lesional tissue ERAP1 level and PASI score. Nonlesional tissue ERAP1 also correlated positively with the PASI score. Conclusion This study, which is the first to measure tissue ERAP1 expression, demonstrated an increased expression in psoriatic skin, in addition to its positive correlation with disease severity. This implied the role of ERAP1 in the pathogenesis of psoriasis, thus encouraging the study of future treatment modalities targeting ERAP1 pathway that could revolutionize treatment for psoriasis. 
546 |a EN 
690 |a antigen processing 
690 |a endoplasmic reticulum aminopeptidase 
690 |a lesional skin 
690 |a nonlesional skin 
690 |a psoriasis 
690 |a Dermatology 
690 |a RL1-803 
655 7 |a article  |2 local 
786 0 |n Journal of the Egyptian Women's Dermatologic Society, Vol 18, Iss 2, Pp 129-134 (2021) 
787 0 |n http://www.jewd.eg.net//article.asp?issn=1687-1537;year=2021;volume=18;issue=2;spage=129;epage=134;aulast=Metwally 
787 0 |n https://doaj.org/toc/2090-2565 
856 4 1 |u https://doaj.org/article/844e906afee74929b644d7afef3fb16c  |z Connect to this object online.